 |
 |
 |
 |
 |
 |
 |
|
|
|
|||||||||
|
|||||||||||
Research Articles |
OBJECTIVE: To report two cases of new-onset diabetes mellitus resulting after the initiation of olanzapine treatment. CASE SUMMARY: A 31-year-old African American man and a 44-year-old white man, both with schizoaffective disorder, developed diabetes mellitus within weeks or months of olanzapine initiation. DISCUSSION: Our reports of new-onset diabetes due to olanzapine are consistent with those in the literature. Although the mechanism is not yet known, it has been hypothesized that perhaps damage to the pancreatic islet cells, weight gain, dysregulation of the sympathetic system, and insulin resistance are contributing factors. CONCLUSIONS: Diabetes mellitus secondary to olanzapine use seems to be a rare occurrence. However, certain risk factors such as obesity, family history, and concomitant medications may predispose an individual to development of diabetes mellitus while taking olanzapine. An increased awareness of this reaction is essential in the treatment of patients at risk. Periodic serum glucose monitoring in these individuals may be warranted.
This article has been cited by other articles:
|
|
 |
|
  I. Kohen, M. Gampel, L. Reddy, and P. Manu Rapidly Developing Hyperglycemia During Treatment with Olanzapine Ann. Pharmacother., April 1, 2008; 42(4): 588 - 591. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. L. Lambert, F. E. Cunningham, D. R. Miller, G. W. Dalack, and K. Hur Diabetes Risk Associated with Use of Olanzapine, Quetiapine, and Risperidone in Veterans Health Administration Patients with Schizophrenia Am. J. Epidemiol., October 1, 2006; 164(7): 672 - 681. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. M. Simpson, I. D. Glick, P. J. Weiden, S. J. Romano, and C. O. Siu Randomized, Controlled, Double-Blind Multicenter Comparison of the Efficacy and Tolerability of Ziprasidone and Olanzapine in Acutely Ill Inpatients With Schizophrenia or Schizoaffective Disorder Am J Psychiatry, October 1, 2004; 161(10): 1837 - 1847. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. B. Sneed and E. C. Gonzalez Type 2 Diabetes Mellitus Induced by an Atypical Antipsychotic Medication J Am Board Fam Med, May 1, 2003; 16(3): 251 - 254. [Full Text] [PDF]
|
|
|
|
 |
|
 M. E.J. Lean and F.-G. Pajonk Patients on Atypical Antipsychotic Drugs: Another high-risk group for type 2 diabetes Diabetes Care, May 1, 2003; 26(5): 1597 - 1605. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. O. Sowell, N. Mukhopadhyay, P. Cavazzoni, S. Shankar, H. O. Steinberg, A. Breier, C. M. Beasley Jr, and J. Dananberg Hyperglycemic Clamp Assessment of Insulin Secretory Responses in Normal Subjects Treated with Olanzapine, Risperidone, or Placebo J. Clin. Endocrinol. Metab., June 1, 2002; 87(6): 2918 - 2923. [Abstract] [Full Text] [PDF]
|
|
 |
 |
 |
 |
 |
 |
 |
